Expression of suppression-related molecules on clinical iTreg products compared with rapa/TGFβ iTregs and UCB tTregs expanded on a research scale with clinically relevant protocols. To assess the expression of suppression-related molecules, clinical rapa/TGFβ iTreg products, aliquots were taken postprocessing and frozen. Frozen aliquots were then thawed and batch-analyzed with rapa/TGFβ iTregs and UCB tTregs expanded on a research scale with clinically relevant protocols for the expression of: CD39 (A), CD73 (B), and (CD103).